The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis - a secondary analysis of a large randomised controlled trial.
about
Identification of developing multiple organ failure in sepsis patients with low or moderate SOFA scores.Predicting the requirement for renal replacement therapy in intensive care patients with sepsisMid-Regional Pro-Adrenomedullin (MR-proADM) as a Biomarker for Sepsis and Septic Shock: Narrative Review
P2860
The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis - a secondary analysis of a large randomised controlled trial.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
The use of mid-regional proadr ...... e randomised controlled trial.
@en
The use of mid-regional proadr ...... e randomised controlled trial.
@nl
type
label
The use of mid-regional proadr ...... e randomised controlled trial.
@en
The use of mid-regional proadr ...... e randomised controlled trial.
@nl
prefLabel
The use of mid-regional proadr ...... e randomised controlled trial.
@en
The use of mid-regional proadr ...... e randomised controlled trial.
@nl
P2093
P2860
P1433
P1476
The use of mid-regional proadr ...... e randomised controlled trial.
@en
P2093
Andreas Weyland
Axel Nierhaus
Darius Cameron Wilson
Frank Bloos
Frank Martin Brunkhorst
Gunnar Elke
Josef Briegel
Konrad Reinhart
Markus Loeffler
Onnen Moerer
P2860
P2888
P356
10.1186/S13054-018-2001-5
P50
P577
2018-03-21T00:00:00Z
P6179
1101677727